Icelandic Salmon (ISLAX) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Jul, 2026Executive summary
Q4 2025 saw positive biological and financial development, with operational EBIT of EUR 2.6 million and a full-year EBIT of EUR -18.1 million, reflecting a strong finish to a challenging year.
Harvested volume for Q4 was 3,800 tonnes, with full-year volume at 12,700 tonnes, slightly below guidance due to volume shifts into Q1 2026.
Stable biological conditions and record-high biomass at year-end supported operational performance.
Positive non-operational effects included a EUR 2.5 million tax refund and a EUR 0.6 million reversal of a previous biomass write-down.
Financial highlights
Operating income for Q4 2025 was EUR 29.4 million, with full-year income at EUR 90.0 million, down from EUR 101.5 million in 2024.
Total assets increased by EUR 10 million to EUR 278 million in Q4, mainly due to a stronger equity position and a EUR 7.5 million fair value adjustment.
Equity ratio improved to 45%, with net interest-bearing debt (including leasing) at EUR 129 million.
Available liquidity at quarter-end was EUR 43 million.
Net debt increased by EUR 7.5 million in Q4, mainly due to higher working capital from strong production and record biomass.
Outlook and guidance
Continued positive operational and financial trends are expected, supported by high sea temperatures and improved biological performance.
Volume guidance for 2026 is 21,300 tonnes, a 67% increase from 2025, with potential to reach 26,000 tonnes on existing licenses.
Contract share expected to rise to 10% in 2026, with a backloaded harvest profile.
CapEx for 2026 projected at EUR 4.77 million, mainly for maintenance.
Market prices expected to strengthen in Q2 2026; contract prices for 2026 anticipated to be higher than 2025.
Latest events from Icelandic Salmon
- Q1 EBIT neared break-even as volumes rose, with stable 2026 outlook despite lower prices.ISLAX
Q1 2026 - Operational loss from high costs, but harvest growth and 2026 recovery expected.ISLAX
Q3 2025 - Operational losses and lower guidance amid biological, regulatory, and market challenges.ISLAX
Q2 2025 - Harvest and EBIT were low in Q3, but strong demand and higher volumes are expected in Q4.ISLAX
Q3 2024 - Biological setbacks drove Q2 and H1 losses, but new licenses and ASC certification support growth.ISLAX
Q2 2024 - Biological setbacks and weak prices drove a Q1 2025 loss, but 2025 guidance is unchanged.ISLAX
Q1 2025 - Stabilized Q4 operations, strong demand, and 2025 volume guidance at 15,000 tonnes.ISLAX
Q4 2024